Bristol-Myers Squibb Applies to Sell New AIDS Drug in Europe
May 30, 2002
Bristol-Myers Squibb said Wednesday it has applied to the European equivalent of the US Food and Drug Administration for clearance to market and sell Atazanavir, a drug currently in development for the treatment of HIV/AIDS. The drug is a viral protease inhibitor that has shown potential for once-daily use, Bristol scientists said. Trials have included more than 1,500 patients whose conditions run the spectrum of HIV infection.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.